Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Clinical Case Reports|November 6, 2023
Percutaneous coronary intervention for ventricular fibrillation in the setting of an anomalous right coronary arteryDanish Saleh, Eric P Cantey, Emily P Marogi, et al.
The Annals of Thoracic Surgery|July 17, 2025
Exercise in Patients With Bicuspid Aortic Valve and Aortic DilationDanish Saleh, Meilynn Shi, S Chris Malaisrie, et al.
European Heart Journal. Imaging Methods and Practice|July 3, 2025
Anterior mitral valve leaflet length and response to mavacamten in obstructive hypertrophic cardiomyopathyDanish Saleh, Ellis Y Kim, Kifah Hussain, et al.
Cell Reports|March 25, 2015
Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1Malek Najjar, Chalada Suebsuwong, Soumya S Ray, et al.
The American Journal of Cardiology|December 26, 2024
Comparison of Alcohol Septal Ablation With Mavacamten in Obstructive Hypertrophic CardiomyopathyAshraf Samhan, Danish Saleh, Ellis Y Kim, et al.
Immunity|July 12, 2016
RIPK1 and RIPK3 Kinases Promote Cell-Death-Independent Inflammation by Toll-like Receptor 4Malek Najjar, Danish Saleh, Matija Zelic, et al.
Chemistry & Biology|September 1, 2015
Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase InhibitorsPeter Canning, Qui Ruan, Tobias Schwerd, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 3, 2017
Kinase Activities of RIPK1 and RIPK3 Can Direct IFN-β Synthesis Induced by LipopolysaccharideDanish Saleh, Malek Najjar, Matija Zelic, et al.
Journal of Cardiovascular Development and Disease|January 27, 2026
Comparison of Diastolic Function Parameters After Alcohol Septal Ablation and Mavacamten Therapy in Obstructive Hypertrophic CardiomyopathyDanish Saleh, Ellis Y Kim, Kifah Hussain, et al.
Pageof 3